| AOD-9604 | GLP-1 & Metabolic | ~30 minutes | Injectable | 300 mcg daily (research protocols) |
| BPC-157 | Healing & Recovery | ~4 hours | Injectable | 250–500 mcg daily |
| Cerebrolysin | Neurological & Cognitive | ~3 hours (peptide fractions) | Injectable | 10–30 mL IV infusion daily for 10–20 day courses |
| CJC-1295 | GH Secretagogues | 6–8 days (with DAC) | Injectable | 1–2 mg weekly |
| CJC-1295 (no DAC) | GH Secretagogues | ~30 minutes | Injectable | Protocol-dependent |
| Dihexa | Neurological & Cognitive | Unknown (limited human pharmacokinetic data) | Topical / Oral / Injectable | Research protocols: ~1 mg/kg topical or oral (no established human dose) |
| DSIP | Neurological & Cognitive | ~30 minutes | Injectable | 25–100 mcg (research; no established human dose) |
| Epithalon | Longevity & Anti-Aging | ~3 hours (estimated) | Injectable | 5–10 mg daily for 10–20 day cycles |
| Follistatin 344 | Healing & Recovery | ~35 hours | Injectable | No established safe human dose — research setting only |
| FOXO4-DRI | Longevity & Anti-Aging | Unknown (D-amino acid resistance to proteolysis extends activity) | Injectable | Mouse studies: 5 mg/kg 3× weekly; human dose not established |
| GHK-Cu | Skin & Aesthetics | ~30 minutes (plasma) | Topical | Topical: varies by formulation (0.1–5%) |
| GHRP-2 | GH Secretagogues | ~30 minutes | Injectable | 100–200 mcg 2–3× daily |
| GHRP-6 | GH Secretagogues | 15–60 minutes | Injectable | 100–200 mcg 2–3× daily |
| Gonadorelin | Hormonal & Endocrine | ~2–10 minutes | Injectable | 100 mcg 2–3× weekly subcutaneous (TRT adjunct protocol) |
| Hexarelin | GH Secretagogues | ~70 minutes | Injectable | 100–200 mcg 2–3× daily |
| HGH (Somatropin) | Hormonal & Endocrine | ~2-3 hours (biologic effects extend via IGF-1) | Injectable | 1-2 IU daily (wellness) to 4-6 IU daily (advanced/off-label); physician protocols vary |
| Humanin | Mitochondrial | ~3 hours (estimated) | Injectable | Research setting only (doses not established for humans) |
| IGF-1 LR3 | GH Secretagogues | 20–30 hours | Injectable | 20–100 mcg daily (research protocols) |
| Ipamorelin | GH Secretagogues | ~2 hours | Injectable | 200–300 mcg 2–3× daily |
| Kisspeptin | Hormonal & Endocrine | ~28 minutes | Injectable | Protocol-dependent |
| KPV | Immune Support | ~1 hour (estimated) | Injectable | 500 mcg–2 mg daily (research protocols) |
| Liraglutide | GLP-1 & Metabolic | ~13 hours | Injectable | 0.6–1.8 mg daily (Victoza); 0.6–3 mg daily (Saxenda) |
| LL-37 | Antimicrobial | ~1 hour (estimated) | Injectable | Research setting (doses not established for humans) |
| Melanotan II | Sexual Health | ~33 minutes | Injectable | Research: 0.5–1 mg (extreme caution; not recommended) |
| MK-677 | GH Secretagogues | ~24 hours | Oral | 10–25 mg daily |
| Mod GRF 1-29 | GH Secretagogues | ~30 minutes | Injectable | 100–200 mcg once or twice daily |
| MOTS-c | Mitochondrial | ~1 hour (estimated) | Injectable | 5–10 mg weekly (research protocols) |
| NAD+ | Longevity & Anti-Aging | ~minutes (IV NAD+); precursor molecules (NMN, NR) have longer stability | Injectable (IV/SubQ) / Oral (precursors) | IV: 250–1000 mg infusion; oral NMN: 250–1000 mg daily |
| Oxytocin | Hormonal & Endocrine | ~3–5 minutes (IV); ~90 minutes (intranasal CNS effect) | Intranasal / Injectable | Intranasal: 20–40 IU; IV: obstetric protocols vary |
| PEG-MGF | Healing & Recovery | ~5 days (PEGylated form) | Injectable | 200–400 mcg 1–2× weekly (research protocols) |
| PT-141 | Sexual Health | ~2.7 hours | Injectable | 1.75 mg subcutaneous (FDA-approved dose) |
| Retatrutide | GLP-1 & Metabolic | ~6 days | Injectable | 0.5–12 mg weekly |
| Selank | Neurological & Cognitive | ~3 minutes (intranasal, active) | Intranasal | 250–500 mcg intranasally 2–3× daily |
| Semaglutide | GLP-1 & Metabolic | ~7 days | Injectable | 0.25–2.4 mg weekly (injectable); 3–14 mg daily (oral) |
| Semax | Neurological & Cognitive | ~7 minutes (active fragment in plasma) | Intranasal | 200–600 mcg intranasally daily |
| Sermorelin | GH Secretagogues | ~11 minutes | Injectable | 200–500 mcg nightly |
| SS-31 | Mitochondrial | ~1.5 hours | Injectable | Clinical trials: 40 mg IV or 40 mg subcutaneous daily |
| TB-500 | Healing & Recovery | ~3 days | Injectable | 2.5–5 mg twice weekly |
| Tesamorelin | GH Secretagogues | ~26 minutes | Injectable | 2 mg once daily |
| Thymosin Alpha-1 | Immune Support | ~2 hours | Injectable | 1.6 mg twice weekly (standard); 3.2 mg twice weekly (intensive) |
| Tirzepatide | GLP-1 & Metabolic | 5 days | Injectable | 2.5–15 mg weekly |
| VIP | Immune Support | ~1–2 minutes (plasma) | Intranasal / Injectable | 50 mcg intranasally twice daily (CIRS protocol) or 200–400 ng/kg IV infusion |
